ProCE Banner Activity

Maximizing Benefit With the Expanding Options for Gastric Cancer: Expert Answers to Frequently Asked Questions

Clinical Thought

In this commentary, an expert faculty addresses questions on the use of contemporary therapeutic regimens for patients with gastric cancer. 

Released: December 22, 2023

Share

Faculty

James M Cleary

James M Cleary, MD, PhD

Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme, LLC.

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

James M Cleary, MD, PhD

Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

James M. Cleary, MD, PhD: consultant/advisor/speaker: Blueprint, Incyte; researcher: GlaxoSmithKline (Tesaro), Merck; other material or financial support: Arcus, AstraZeneca, Esperas Pharma, Pyxis, owner: Bayer; data safety monitoring board: AstraZeneca.